鱼胶原蛋白水解物在骨质疏松预防中的治疗潜力:基于细胞、分子和临床证据的叙述性综述
本文为叙述性综述,评估鱼胶原蛋白水解物(FCHs)对骨细胞生物学作用的临床前与临床证据,讨论其高生物利用度、生物相容性及对骨代谢的影响,并汇总骨密度增加和骨微结构改善的体内证据及相关调控标志物;早期临床试验提示对骨转换和骨密度有益,但仍需大规模随机研究证实。
要点
- 鱼胶原蛋白水解物(FCHs)源自鱼类加工废弃物,是安全、廉价且环境友好的哺乳动物胶原替代品。
- 综述汇总了FCHs在体内增加骨密度、改善骨微结构的证据及成骨/破骨细胞调控标志物。
- 早期临床试验提示FCHs对骨转换和骨密度有益,但仍需大规模随机研究证实。
核心结论
- FCHs在骨质疏松预防和管理中是有前景但仍处于发展阶段的治疗途径。
- 早期临床试验提示FCHs对骨转换和骨密度有益,但仍需稳健的大规模随机研究证实这些发现。
研究设计与样本
- 本文为叙述性综述,批判性评估FCHs对骨细胞生物学治疗有效性的临床前和临床证据。
主要发现
- 综述讨论了FCHs的高生物利用度、生物相容性及鱼胶原蛋白肽影响骨代谢的潜力。
- 体内证据显示FCHs可增加骨密度并改善骨微结构。
- 综述涉及成骨细胞和破骨细胞功能的关键调控标志物,包括碱性磷酸酶(ALP)、骨钙素(OCN)、骨桥蛋白(OPN)、Runt相关转录因子-2(Runx-2)、骨形态发生蛋白-2(BMP-2)、核因子κB受体活化因子配体(RANKL)、抗酒石酸酸性磷酸酶(TRAP)和组织蛋白酶K。
局限性
- 早期临床试验虽提示FCHs对骨转换和骨密度有益,但仍需稳健的大规模随机研究证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Osteoporosis is a prevalent bone disorder diagnosed by diminished bone density and deterioration of skeletal microarchitecture. Adverse side effects caused by the prolonged use of anti-osteoporotic medications have prompted researchers to find safe and natural therapeutic compounds to manage osteoporosis. Among natural compounds, fish collagen hydrolysates (FCHs) derived from fish processing wastes offer a safe, inexpensive, and environment-friendly alternative to mammalian collagen. This review critically evaluates the preclinical and clinical evidence for the therapeutic effectiveness of FCHs on bone cell biology, highlighting their potential in osteoporosis prevention. The review also highlights high bioavailability, biocompatibility, and the potential of fish collagen peptides to influence bone metabolism. Evidence of increased bone mineral density and improved bone microarchitecture has also been discussed in vivo, along with key regulatory markers of osteoblasts and osteoclasts function, including alkaline phosphatase (ALP), osteocalcin (OCN), osteopontin (OPN), runt-related transcription factor-2 (Runx-2), bone morphogenetic protein (BMP-2), receptor activator of nuclear factor κ B ligand (RANKL), tartrate-resistant acid phosphatase (TRAP), and cathepsin K. Although early clinical trials suggest beneficial effects on bone turnover and bone mineral density, robust, large-scale randomized studies are still needed to confirm these findings. FCHs thus present a promising but still developing therapeutic avenue in the prevention and management of osteoporosis.
引用
- Alvi A, Parashar K, Siddiqui S, et al. Therapeutic potential of fish collagen hydrolysates in osteoporosis prevention: a narrative review based on cellular, molecular, and clinical evidence. Osteoporos Int. 2025. PMID: 41028243. doi:10.1007/s00198-025-07698-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。